Head to Head Review: KalVista Pharmaceuticals (NASDAQ:KALV) & Nuvilex (NASDAQ:PMCB)

Nuvilex (NASDAQ:PMCB) and KalVista Pharmaceuticals (NASDAQ:KALV) are both small-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their valuation, analyst recommendations, profitability, dividends, earnings, risk and institutional ownership.

Profitability

This table compares Nuvilex and KalVista Pharmaceuticals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Nuvilex	N/A	2.13%	1.69%
KalVista Pharmaceuticals	N/A	-214.88%	-81.87%

Valuation & Earnings

This table compares Nuvilex and KalVista Pharmaceuticals”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvilex	N/A	N/A	$30.66 million	($1.12)	-0.65
KalVista Pharmaceuticals	N/A	N/A	-$183.44 million	($3.95)	-4.20

KalVista Pharmaceuticals is trading at a lower price-to-earnings ratio than Nuvilex, indicating that it is currently the more affordable of the two stocks.

Institutional and Insider Ownership

34.2% of Nuvilex shares are owned by institutional investors. 11.0% of Nuvilex shares are owned by company insiders. Comparatively, 4.3% of KalVista Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Risk & Volatility

Nuvilex has a beta of 0.33, meaning that its stock price is 67% less volatile than the S&P 500. Comparatively, KalVista Pharmaceuticals has a beta of -0.35, meaning that its stock price is 135% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings for Nuvilex and KalVista Pharmaceuticals, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvilex	1	0	0	0	1.00
KalVista Pharmaceuticals	1	0	7	0	2.75

KalVista Pharmaceuticals has a consensus price target of $29.40, indicating a potential upside of 77.11%. Given KalVista Pharmaceuticals’ stronger consensus rating and higher probable upside, analysts plainly believe KalVista Pharmaceuticals is more favorable than Nuvilex.

Summary

Nuvilex beats KalVista Pharmaceuticals on 8 of the 11 factors compared between the two stocks.

About Nuvilex

PharmaCyte Biotech, Inc., a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer. The company develops CypCaps for pancreatic cancer and other solid cancerous tumors. It has a cooperation agreement with Iroquois Master Fund Ltd.; and license agreements with SG Austria Pte. Ltd. and Austrianova Singapore Pte. Ltd. to use the Cell-in-the-Box technology for cancer treatment. The company was formerly known as Nuvilex, Inc. and changed its name to PharmaCyte Biotech, Inc. in January 2015. PharmaCyte Biotech, Inc. was incorporated in 1996 and is headquartered in Las Vegas, Nevada.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company’s product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.